Bone Rx Boosted Breast Cancer Survival
Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.
Medicines to Prevent Osteoporosis Fractures Were Effective
The risk of broken bones increases with age and is a major cause of disability and death in older people. But some treatments may prevent bone fractures.
Breaking News on Osteoporosis Medications
Women with osteoporosis (brittle bones) have two effective treatment choices: Prolia (denosumab) and Reclast (zoledronic acid). So which is more effective? A recent study did a side-by-side comparison.
Rx Tag-Team Works Better for Weak Bones
When one medicine doesn't help postmenopausal women with osteoporosis, doctors might recommend another. But if the second doesn't strengthen bones, what happens then? Taking them together might do the trick.
Giant Step Forward for Giant-Cell Tumor of the Bone
Denosumab – sold under the brand names of Prolia for the treatment of osteoporosis and Xgeva for fracture prevention in patients with metastatic cancers to the bone – may be effective in treating people with a condition known as giant-cell tumor of the bone.
Which Bone Metastasis Drug Is Better?
When breast cancer spreads to the bones, various drugs are available to control the disease. This class of drugs is called biophosphonates . A manufacturer-funded study suggests its drug is better than others.
FDA Approves Prolia for osteoporosis
On September 16, 2011, the U.S. Food and Drug Administration granted approval for denosumab ( Prolia , Amgen Inc.) as a treatment to increase bone mass in patients at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer or adjuvant aromatase inhibitor (AI) therapy for breast cancer. In men with nonmetastatic prostate cancer, denosumab also reduced the incidence of vertebral fracture.